Very bullish for
TRVN
in the long term.
- High demand product with blockbuster drug good for opiod crisis.
- Potential replacement for morphine, no real competitor
- Partnership with Syneos for sales
- Potential buyout
Good levels to buy at 2.50 and 2.33
Should see rise towards next quarter earnings.
Long term PTs
TP1 - $5
TP2 - $15
TP3 - $30
TRVN
in the long term. - High demand product with blockbuster drug good for opiod crisis.
- Potential replacement for morphine, no real competitor
- Partnership with Syneos for sales
- Potential buyout
Good levels to buy at 2.50 and 2.33
Should see rise towards next quarter earnings.
Long term PTs
TP1 - $5
TP2 - $15
TP3 - $30
Komen:
hold
Komen:
Falling wedge pattern in the short term and an ascending triangle on the mid term.
Continue hold towards next quarter earnings in March
Falling wedge pattern in the short term and an ascending triangle on the mid term.
Continue hold towards next quarter earnings in March
Dagangan aktif:
Komen:
Seems to breaking out of the falling wedge